

This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.

February 25, 2026  
MatsukiyoCocokara & Co.

### **MC & C Fund to Invest in Metagen Therapeutics, Inc.**

MatsukiyoCocokara & Co. (HQ: Bunkyo-ku, Tokyo; President and Representative Director: Kiyoo Matsumoto; hereinafter the "Company") has established its Management Philosophy as "Creating the future normal and innovating lifestyles." Guided by our Group Vision of "Making health and beauty and more delightful and accessible," we operate within the health and beauty sectors as our core business domains. By providing unique value and experiences, we are dedicated to helping our customers realize their aspirations for health and beauty.

The Company has invested in Metagen Therapeutics, Inc. (HQ: Tsuruoka-shi, Yamagata; President & CEO: Taku Nakahara; hereinafter "Metagen Therapeutics"), a company engaged in advancing microbiome research-based healthcare services and drug discovery, as a company related to new business creation from MC & C Investment Limited Partnership (hereinafter "MC & C Fund").



**MatsukiyoCocokara & Co.**

Metagen Therapeutics is a startup founded in 2020 with the purpose of "Living up to the hopes of patients through microbiome science." Through the real-world implementation of "Fecal Microbiota Transplantation (FMT)," it aims to deliver microbiome-based medical care to patients in Japan and around the world. To date, Metagen Therapeutics has built an end-to-end supply chain spanning donor and stool collection through to the manufacture of investigational drugs, and is advancing research and development of therapeutics and related solutions for multiple diseases, including ulcerative colitis.

Through the MC & C Fund, the Company will create "The Future Normal" that Metagen Therapeutics' "intestinal microbiome medicine" will be the standard of care worldwide, and support efforts to provide society with new treatments for intractable diseases. At the same time, the Company aims to realize a society where customers and patients can live healthy lives through an approach to the intestinal environment.

MatsukiyoCocokara & Co. will continue to invest in and support venture companies that can grow together in the areas of strengthening the existing business, creating a new business, and innovation.

#### Profile of Metagen Therapeutics

Company name	Metagen Therapeutics, Inc.
Title and name of the representative	Taku Nakahara President & CEO
Head office	246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0052
Established	January 2020
Business description	Pharmaceutical and Medical Business Utilizing Microbiome Science
URL	<a href="https://www.metagentx.com/">https://www.metagentx.com/</a>